| Transitional Cell Carcinoma predicts response to …PREDICTS_RESPONSE_TO20 of 20show fewer |
|---|
| in context · predicts response to | FGFR3 Mutationother → predicts response to Erdafitinib | sensitivity | A | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | FGFR2 Fusionfusion → predicts response to Erdafitinib | sensitivity | A | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | FGFR2 Fusionfusion → predicts response to Erdafitinib | sensitivity | A | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | FGFR2 Mutationother → predicts response to Erdafitinib | sensitivity | A | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | ERBB3 G284RSNV → predicts response to Afatinib | sensitivity | B | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | ERBB3 R103GSNV → predicts response to Afatinib | sensitivity | B | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | ERBB3 V104MSNV → predicts response to Afatinib | sensitivity | B | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | FGFR3 S249CSNV → predicts response to Pazopanib | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | MTOR E2014KSNV → predicts response to Everolimus | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | MTOR E2014KSNV → predicts response to Pazopanib | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | MTOR E2419KSNV → predicts response to Everolimus | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | MTOR E2419KSNV → predicts response to Pazopanib | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | BRAF Fusionfusion → predicts response to Trametinib | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | TACC3 Fusionfusion → predicts response to Infigratinib | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | BICC1 Fusionfusion → predicts response to Erdafitinib | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | MSH6 LOSSdeletion_cna → predicts response to Anti-PD-1 Monoclonal Antibody MEDI0680 | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | MSH6 LOSSdeletion_cna → predicts response to Durvalumab | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | MSH2 Lossdeletion_cna → predicts response to Anti-PD-1 Monoclonal Antibody MEDI0680 | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | MSH2 Lossdeletion_cna → predicts response to Durvalumab | sensitivity | C | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |
| in context · predicts response to | FGFR3 S249CSNV → predicts response to Cisplatin | resistance | D | Transitional Cell Carcinoma | 1 | Curated | civic | graph → |